<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837967</url>
  </required_header>
  <id_info>
    <org_study_id>D589LC00003</org_study_id>
    <nct_id>NCT00837967</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients</brief_title>
  <official_title>A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler®
      160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on
      top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 days</time_frame>
    <description>Total number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)</measure>
    <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
    <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)</measure>
    <time_frame>up to 140 min after start dosing for each treatment day</time_frame>
    <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)</measure>
    <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
    <description>The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)</measure>
    <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
    <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)</measure>
    <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
    <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>First Symbicort, then Terbutaline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Turbuhaler, then Symbicort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler</intervention_name>
    <description>160/4.5μg for 3 days</description>
    <arm_group_label>First Symbicort, then Terbutaline</arm_group_label>
    <arm_group_label>First Turbuhaler, then Symbicort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline Turbuhaler</intervention_name>
    <description>0.4 mg for 3 days</description>
    <arm_group_label>First Symbicort, then Terbutaline</arm_group_label>
    <arm_group_label>First Turbuhaler, then Symbicort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006
             definition

          -  FEV1&gt; 70% of predicted normal value pre-bronchodilator

        Exclusion Criteria:

          -  Having a known or suspected allergy to study therapy (active drugs or additive)

          -  Having a known clinical history of hypertension, relevant arrhythmias or other heart
             disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart
             failure

          -  Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or
             with depot parenteral glucocorticoids within 3 months

          -  Respiratory infection significantly affecting the asthma, as judged by the
             investigator within 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaragi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <results_first_submitted>July 5, 2010</results_first_submitted>
  <results_first_submitted_qc>August 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2012</results_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Symbicort Turbuhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from 2 hospitals in Japan between January 2009 and July 2009. 28 patients enrolled; 25 patients randomized, 3 patients were not randomized (1 due to incorrect enrollment and 2 due to adverse event)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort First, Then Terbutaline</title>
          <description>Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Terbutaline First, Then Symbicort</title>
          <description>Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 7 - 14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Total number of adverse events</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Total number of adverse events</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)</title>
        <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
        <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)</title>
          <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="0.25"/>
                    <measurement group_id="O2" value="3.88" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)</title>
        <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
        <time_frame>up to 140 min after start dosing for each treatment day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)</title>
          <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
          <units>mg/dLiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="20.3"/>
                    <measurement group_id="O2" value="129.5" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)</title>
        <description>The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia’s formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
        <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)</title>
          <description>The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia’s formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.71" spread="15.07"/>
                    <measurement group_id="O2" value="414.33" spread="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)</title>
        <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
        <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)</title>
          <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="6.3"/>
                    <measurement group_id="O2" value="114.9" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)</title>
        <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
        <time_frame>up to 740 min after start dosing for each treatment day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort Turbuhaler 160/4.5μg</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline</title>
            <description>Terbutaline Turbuhaler 0.4 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)</title>
          <description>The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.</description>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="6.6"/>
                    <measurement group_id="O2" value="74.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Of 25 patients in safety analysis set, 2 patients did not receive terbutaline due to adverse events lead to discontinuation. Therefore, data from 25 patients for Symbicort and 23 patients for terbutaline were used for the safety evaluation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Symbicort</title>
          <description>Symbicort Turbuhaler 160/4.5μg for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Terbutaline</title>
          <description>Terbutaline Turbuhaler 0.4 mg for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

